A federally funded trial tested fisetin in COVID-positive nursing home residents. It didn’t test long COVID, and no dedicated fisetin long-COVID trial exists. Here’s the real research, not the version that gets shared online.
Across four different mouse models of kidney injury, fisetin consistently reduced senescent cell burden and fibrosis. But one study found no improvement in actual kidney function. Here’s what that gap means.
Age-related macular degeneration (AMD) is the leading cause of vision loss in older adults in Western countries, and researchers increasingly
Most fisetin coverage focuses on senescent cells in fat, skin, or connective tissue. Less discussed is a specific and well-documented
Fisetin improved frailty and grip strength in old, sedentary mice, with no effect in young ones. That distinction matters for anyone hoping it’s a performance enhancer rather than an anti-aging tool.
Fisetin’s senescent-cell-clearing mechanism touches ovarian aging, bone loss, and hormonal decline, all central to perimenopause. Here’s what the preclinical research shows, and why no human trial has tested it yet.
Senescent cells accumulate in aging gut tissue too. Here’s what mouse colitis and Parkinson’s-model research shows about fisetin, the gut lining, and the microbiome.
Osteoarthritis is, at its core, a disease of cartilage breakdown, and a growing body of research has identified senescent chondrocytes,
Fisetin’s reputation rests almost entirely on one mechanism: senolysis, the selective clearance of senescent ‘zombie’ cells. But a separate and
Fisetin is under study as a senolytic compound that may clear senescent cells in the dermis. Here is what the current evidence actually shows.
Fisetin is studied as a senolytic targeting ‘zombie’ cells. Here’s an honest look at what mouse research shows, and what remains unknown in humans.
Fisetin is studied as a senolytic and senomorphic agent that may reduce SASP-driven inflammation. Here is what the current preclinical evidence actually shows.